Yasuhiro Kondoh
Elite in Interstitial Lung Disease

Yasuhiro Kondoh

Drs. Yokoyama And Kondoh Are Affiliated With Department Of Respiratory Medicine And Allergy, 
Seto, JP 
Elite in Interstitial Lung Disease
Drs. Yokoyama And Kondoh Are Affiliated With Department Of Respiratory Medicine And Allergy, 
Seto, JP 
OverviewLocationsClinical Research

Overview

Yasuhiro Kondoh practices in Seto, Japan. Mr. Kondoh is rated as an Elite expert by MediFind in the treatment of Interstitial Lung Disease. His top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, and Endoscopy.

His clinical research consists of co-authoring 226 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 177 articles and participated in 2 clinical trials in the study of Interstitial Lung Disease.

Gender
Male

Locations

Drs. Yokoyama And Kondoh Are Affiliated With Department Of Respiratory Medicine And Allergy, Seto, Japan
Other Locations
Nagakute, Japan
Okazaki, Japan
Japan
Tokyo, 1698555, Japan
Nagoya, Japan
Wako, Japan
Saitama, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Drug, Other
Study Drug: ND-L02-s0201
Study Phase: Phase 2
View 1 Less Clinical Trial

226 Total Publications

PaO2/FIO2-Based Stratification Discriminates Treatment Failure in Nonintubated Subjects With ARDS.
PaO2/FIO2-Based Stratification Discriminates Treatment Failure in Nonintubated Subjects With ARDS.
Journal: Respiratory care
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kondoh's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile